|Description||OSI-420 (CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells.|
|B0084-286627||10 mg||$198||In stock|
|B0084-286627||50 mg||$598||In stock|
|Synonyms||OSI420; OSI-420; OSI 420; CP473420; CP-473420; CP 473420; Desmethyl Erlotinib.|
|Application||For research used only|
XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...
WZ-4002 is an EGFR phosphorylation inhibitor with selectivity for EGFR T790M. It has a framework of pyrimidine compound which is different from other EGFR inhib...
BMS-599626 Hydrochloride is a selective and efficacious orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases with potential antineoplastic ...
CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbourin...
WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...
WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.
RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.
Trastuzumab is a monoclonal antibody drug for the treatment of breast cancer which is HER2 receptor positive. It acts via binding to HER2 receptor to suppress c...